查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1715573

急性肾损伤治疗市场（依治疗类型、急性肾损伤类型、最终使用者、患者人口统计）－2025 年至 2030 年全球预测

Acute Kidney Injury Treatment Market by Treatment Type, AKI Type, End User, Patient Demographics - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 193 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2024年急性肾损伤治疗市值为20.2亿美元，预计2025年将达21.8亿美元，预计年复合成长率为7.83%，到2030年将达到31.8亿美元。

主要市场统计数据
基准年2024年 20.2亿美元
预计2025年 21.8亿美元
预测年份 2030 31.8亿美元
复合年增长率（%） 7.83%

急性肾损伤 (AKI) 是一种日益严重的疾病，不仅需要快速的临床干预，还需要采取策略性的治疗方式。本报告全面介绍了 AKI 治疗的广阔前景，为理解塑造该行业的动态、创新和监管变化奠定了基础。它关注治疗通讯协定的逐步演变和颠覆传统范式的新趋势。当决策者努力平衡成本效益和患者结果时，了解最新进展至关重要。

在此背景下，该报告深入研究了现有的治疗方法、最尖端科技和不断发展的患者管理策略。该报告旨在成为医疗保健专业人士、行业领导者和政策制定者寻求改善患者治疗结果同时优化资源配置和业务效率的重要工具。本书透过对市场趋势、临床实践和法律规范的全面整合，为 AKI 治疗的策略规划奠定了坚实的知识基础。

重新定义 AKI 治疗格局的转捩点

科技的快速进步、新颖的治疗策略以及越来越多的整体患者照护方法正在迅速改变急性肾损伤治疗模式。在本节中，我们将探讨其中的一些变化以及它们如何推动临床和业务变革。

透析技术的创新发展，包括连续性肾臟替代疗法、间歇性血液透析机以及连续性低效透析的整合，彻底改变了临床医师处理肾臟支持的方式。药物治疗的进步，从抗生素和利尿剂到先进的疼痛管理和补液剂，现在可以提供更有针对性的干预措施，减少副作用并改善临床结果。此外，强调饮食和液体管理的支持性护理对于稳定患者病情、弥合急性护理和长期管理之间的差距至关重要。

数位医疗记录、预测分析和远端医疗的整合实现了即时监控和更动态的护理调整。这将带来一个更具回应性的护理生态系统，其中治疗决策将由硬数据和持续的患者回馈来决定。此外，製药公司、技术开发商和医疗保健提供者之间的合作正在打破传统的孤岛，创造一个成熟的创新环境，促进救生技术的快速应用。

为了因应这些巨大的变化，医疗保健融资结构和报销模式也在不断发展。政策改革和对生物医学研究的投入增加正在为更永续的以患者为中心的护理铺平道路。临床创新、医疗数位化和策略性投资的整合正在重新定义 AKI 的管理方式，最终将模式从被动照护转变为预防性医疗管理。

关键细分洞察，为您的市场策略提供参考

对 AKI 治疗市场的详细分析揭示了製定有针对性的策略所需的多层次细分。主要细分之一是治疗类型，分为透析、药物治疗和支持性护理。透析治疗又分为连续性肾臟替代治疗、间歇性血液透析机、连续性低效率透析，各有其优点及临床考量。同时，药物治疗分为抗生素、利尿剂、止痛治疗方法和补液药等类别，强调了根据每位患者的需求量身定制个人化医疗介入的重要性。支持性护理领域以饮食和液体管理为重点，在透过整体患者照护补充这些干预措施方面发挥着重要作用。

另一个重要的分类标准是AKI的类型，可以是原发性肾损伤、肾后性急性肾损伤或肾前性急性肾损伤。这种分类对于指导临床决策和确定最佳治疗方法至关重要。此外，最终用户细分涵盖了主要的医疗保健机构，例如门诊手术中心、医院和专科诊所，凸显了需要适应不同环境的治疗通讯协定。此外，成人、老年人和儿科等患者人口统计细分凸显了治疗反应的多变性，需要分层治疗通讯协定来有效满足每个群体的独特需求。

从这些不同的细分标准中获得的见解为制定全面而有针对性的策略倡议提供了基础。这将使相关人员能够更有效地分配资源，准确预测市场趋势，并根据特定的临床情况量身定制治疗方法。这种细分主导的方法对于建立能够满足当前需求并预测 AKI 治疗领域未来变化的弹性生态系统至关重要。

目录

第一章 引言

第二章调查方法

第三章执行摘要

第四章 市场概述

第五章 市场洞察

  • 市场动态
    • 驱动程式
      • 人口老化导致全球急性肾损伤发生率上升
      • 由于文明病的增加，预计急性肾损伤治疗的需求将会增加
      • 政府措施和医疗改革促进肾臟疾病良好照护基础设施
    • 限制因素
      • 与急性肾损伤治疗相关的产品召回问题
    • 机会
      • 医疗保健合作加速急性肾损伤治疗方法的开发
      • 改进的诊断技术使得早期发现急性肾损伤和进行治疗成为可能。
    • 任务
      • 目前药物治疗的副作用和不良反应限制了其广泛使用。
  • 市场区隔分析
    • 治疗类型：透过温和、连续的过滤过程使用连续肾臟替代疗法。
    • 患者人口统计：由于肾功能的自然衰退，老年患者的急性肾损伤治疗增加
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社会
    • 技术的
    • 合法的
    • 环境

6. 急性肾损伤治疗市场（依治疗类型）

  • 透析
    • 持续性肾臟替代治疗（CRRT）
    • 间歇性血液透析机
    • 持续低效透析（SLED）
  • 药物治疗
    • 抗生素
    • 利尿剂
    • 疼痛管理药物
    • 补液药物
  • 支持治疗
    • 饮食管理
    • 液体管理

第七章急性肾损伤治疗市场-AKI类型

  • 肾内源性急性肾损伤
  • 肾后性急性肾损伤
  • 肾前性急性肾损伤

第八章急性肾损伤治疗市场（依最终使用者）

  • 门诊手术中心
  • 医院
  • 专科诊所

9. 急性肾损伤治疗市场（依患者人口统计）

  • 成年患者
  • 老年患者
  • 儿科患者

10.美洲急性肾损伤治疗市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

11. 亚太地区急性肾损伤治疗市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

12. 欧洲、中东和非洲急性肾损伤治疗市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十三章竞争格局

  • 2024年市场占有率分析
  • 2024年FPNV定位矩阵
  • 竞争情境分析
  • 战略分析与建议

公司名单

  • Abbott Laboratories
  • Alloksys Life Sciences BV
  • Amgen Inc.
  • Asahi Kasei Medical Co., Ltd.
  • Astellas Pharma Inc.
  • B. Braun Melsungen AG
  • Baxter International, Inc.
  • Bayer AG
  • bioMerieux SA
  • CardioRenal Systems, Inc.
  • DaVita Inc. by Optum, Inc.
  • Dr. Reddys Laboratories Ltd.
  • Elicio Therapeutics Inc
  • Fresenius Medical Care AG & Co. KGaA
  • GlaxoSmithKline PLC
  • Merck & Co., Inc.
  • Nipro Corporation
  • Novartis AG
  • Otsuka Pharmaceutical Co., Ltd.
  • Pfizer Inc.
  • Silver Creek Pharmaceuticals, Inc.
  • Sysmex Corporation
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd.
Product Code: MRR-035DA3C63706

The Acute Kidney Injury Treatment Market was valued at USD 2.02 billion in 2024 and is projected to grow to USD 2.18 billion in 2025, with a CAGR of 7.83%, reaching USD 3.18 billion by 2030.

KEY MARKET STATISTICS
Base Year [2024] USD 2.02 billion
Estimated Year [2025] USD 2.18 billion
Forecast Year [2030] USD 3.18 billion
CAGR (%) 7.83%

Acute Kidney Injury (AKI) is an increasingly significant medical condition that demands not only prompt clinical intervention but also a strategic approach in treatment methodologies. This report offers a comprehensive exploration of the vast landscape of AKI treatment, laying the groundwork for understanding the dynamics, innovations, and regulatory shifts that shape this industry. The focus is on the progressive evolution of treatment protocols and emerging trends that have recast traditional paradigms. As decision-makers strive to balance cost-effectiveness and patient outcomes, understanding the latest advancements becomes imperative.

In this context, the report navigates through a detailed investigation into the therapeutic modalities available, cutting-edge technologies, and evolving patient management strategies. It is designed to serve as a critical tool for healthcare professionals, industry leaders, and policy makers who are committed to enhancing patient prognosis while simultaneously optimizing resource allocation and operational efficiencies. With a meticulous synthesis of market trends, clinical practices, and regulatory frameworks, this discussion lays a strong intellectual foundation for strategic planning in the arena of AKI treatment.

Transformative Shifts Redefining the AKI Treatment Landscape

The landscape of Acute Kidney Injury treatment is undergoing a radical transformation driven by rapid advancements in technology, novel therapeutic strategies, and an increasingly holistic approach to patient care. This section delves into these transformative shifts and how they are reshaping both clinical and business practices.

Innovative developments in dialysis techniques, such as the integration of continuous renal replacement therapy, intermittent hemodialysis, and sustained low-efficiency dialysis, have revolutionized the way clinicians approach renal support. The evolution of pharmacological treatments, from antibiotics and diuretics to sophisticated pain management and rehydration drugs, now offers more targeted interventions, reducing adverse effects and improving clinical outcomes. Furthermore, supportive care strategies that emphasize dietary and fluid management have become indispensable in stabilizing patients, bridging the gap between acute intervention and long-term management.

The integration of digital health records, predictive analytics, and telemedicine is enabling real-time monitoring and more dynamic treatment adjustments. This leads to a more responsive care ecosystem, where therapeutic decisions are informed by robust data and continuous patient feedback. In addition, the cross-collaboration between pharmaceutical companies, technology developers, and healthcare providers is fostering an environment ripe for innovation, breaking traditional silos and facilitating the rapid adoption of life-saving technologies.

In the wake of these dramatic shifts, financial structures and reimbursement models in healthcare are also evolving. Policy reforms and increased investments in biomedical research are paving the way for a more sustainable and patient-centered approach to treatment. This confluence of clinical innovation, healthcare digitization, and strategic investments is redefining how AKI is managed, ultimately shifting the paradigm from reactive care to proactive and preventive health management.

Key Segmentation Insights Informing Market Strategies

A granular analysis of the AKI treatment market reveals numerous layers of segmentation that are crucial for developing targeted strategies. One of the primary segmentation aspects considers treatment type, where the market is dissected into dialysis, pharmacological treatment, and supportive care. Dialysis methods are refined further into modalities such as continuous renal replacement therapy, intermittent hemodialysis, and sustained low-efficiency dialysis, each demonstrating unique advantages and clinical considerations. Meanwhile, pharmacological treatments branch out into categories including antibiotics, diuretics, pain management drugs, and rehydration drugs, which collectively underscore the importance of personalized medical interventions tailored to individual patient needs. The supportive care segment, centered around dietary and fluid management, plays a critical role in complementing these interventions with holistic patient care.

Another important segmentation criterion is the type of AKI, which can manifest as intrinsic renal, post-renal, or pre-renal acute kidney injury. This classification is pivotal in guiding clinical decision-making and determining the optimal therapeutic approach. Additionally, the end user segmentation covers key healthcare settings such as ambulatory surgical centers, hospitals, and specialty clinics, emphasizing the need for adaptable treatment protocols across diverse environments. Furthermore, patient demographics segmentation-including adult, geriatric, and pediatric populations-highlights the variability in treatment responses, necessitating stratified care protocols to effectively address the unique needs of each group.

The combined insights from these varied segmentation criteria provide a basis for developing strategic initiatives that are both comprehensive and precise. They enable stakeholders to allocate resources more efficiently, forecast market trends accurately, and tailor treatment options to specific clinical scenarios. This segmentation-driven approach is essential for building a resilient ecosystem capable of both meeting current demands and anticipating future shifts in the AKI treatment landscape.

Based on Treatment Type, market is studied across Dialysis, Pharmacological Treatment, and Supportive Care. The Dialysis is further studied across Continuous Renal Replacement Therapy (CRRT), Intermittent Hemodialysis, and Sustained Low-Efficiency Dialysis (SLED). The Pharmacological Treatment is further studied across Antibiotics, Diuretics, Pain Management Drugs, and Rehydration Drugs. The Supportive Care is further studied across Dietary Management and Fluid Management.

Based on AKI Type, market is studied across Intrinsic Renal Acute Kidney Injury, Post-renal Acute Kidney Injury, and Pre-renal Acute Kidney Injury.

Based on End User, market is studied across Ambulatory Surgical Centers, Hospitals, and Specialty Clinics.

Based on Patient Demographics, market is studied across Adult Patients, Geriatric Patients, and Pediatric Patients.

Key Regional Insights Shaping the Global Market

The geographical diversification in the AKI treatment market is robustly characterized by distinct regional dynamics across the Americas, Europe, Middle East & Africa, and Asia-Pacific. In the Americas, a mature healthcare infrastructure and progressive regulatory frameworks have facilitated the rapid adoption of cutting-edge treatment modalities. Innovations in both dialysis and pharmacological therapies are widely recognized throughout this region, bolstering high clinical outcomes and advancing patient care protocols.

In Europe, Middle East & Africa, a combination of state-of-the-art research facilities and patient-centric healthcare systems is driving significant growth. Regulatory harmonization and strategic investments in research and development have facilitated the implementation of novel treatment strategies across these regions. Particularly, the integration of supportive care initiatives and digital health technologies has enhanced both diagnostic precision and therapeutic responsiveness.

The Asia-Pacific region, known for its dynamic economic growth and expansive population base, presents formidable opportunities due to rising healthcare expenditures and increasing awareness about kidney health. Advancements in technology, combined with a strong emphasis on local clinical research, are fostering a more competitive market environment. Overall, these regional insights underscore the varied yet interconnected nature of the global AKI treatment ecosystem, reinforcing the need for region-specific strategies to address local challenges while leveraging international trends.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The competitive landscape in the AKI treatment market is shaped by numerous influential companies that drive innovation and clinical excellence. Industry leaders such as Abbott Laboratories and Alloksys Life Sciences B.V. have established strong presences through continuous investments in research and development, while companies like Amgen Inc. champion advanced therapeutic solutions. Prominent contributions from Asahi Kasei Medical Co., Ltd. and Astellas Pharma Inc. underscore the importance of diversified portfolios in addressing the multifaceted nature of AKI.

Market players including B. Braun Melsungen AG, Baxter International, Inc., and Bayer AG have been instrumental in developing state-of-the-art devices and pharmacological treatments that continue to improve clinical outcomes. BioMerieux SA brings diagnostic precision into focus, while CardioRenal Systems, Inc. emphasizes integrated care solutions tailored to modern healthcare needs. Strategic collaborations and advancements from companies such as DaVita Inc. by Optum, Inc. and Dr. Reddys Laboratories Ltd. further showcase the level of innovation permeating the industry.

Additional contributions from Elicio Therapeutics Inc, Fresenius Medical Care AG & Co. KGaA, GlaxoSmithKline PLC, and Merck & Co., Inc. highlight the critical role of cross-disciplinary synergy. Companies such as Nipro Corporation, Novartis AG, Otsuka Pharmaceutical Co., Ltd., and Pfizer Inc. continue to set benchmarks in safety, efficacy, and technological advancements, while Silver Creek Pharmaceuticals, Inc., Sysmex Corporation, Takeda Pharmaceutical Company Limited, and Teva Pharmaceutical Industries Ltd. emphasize the global reach and scope of current research and marketing strategies. In summation, these key companies not only drive the market through innovative solutions and robust product pipelines but also shape the strategic direction of AKI treatment on a worldwide scale.

The report delves into recent significant developments in the Acute Kidney Injury Treatment Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Alloksys Life Sciences B.V., Amgen Inc., Asahi Kasei Medical Co., Ltd., Astellas Pharma Inc., B. Braun Melsungen AG, Baxter International, Inc., Bayer AG, bioMerieux SA, CardioRenal Systems, Inc., DaVita Inc. by Optum, Inc., Dr. Reddys Laboratories Ltd., Elicio Therapeutics Inc, Fresenius Medical Care AG & Co. KGaA, GlaxoSmithKline PLC, Merck & Co., Inc., Nipro Corporation, Novartis AG, Otsuka Pharmaceutical Co., Ltd., Pfizer Inc., Silver Creek Pharmaceuticals, Inc., Sysmex Corporation, Takeda Pharmaceutical Company Limited, and Teva Pharmaceutical Industries Ltd.. Actionable Recommendations for Industry Leaders

Industry leaders are prompted to adopt a multifaceted approach in navigating the changing landscape of AKI treatment. To remain competitive, companies should prioritize investment in research and development to foster innovative treatment modalities that address diverse patient needs. It is essential to embrace a collaborative ethos-an approach that bridges the gap between clinical research and commercial execution. Building strategic partnerships, not only within the healthcare ecosystem but also with technological innovators, can yield outcomes that extend beyond conventional treatment paradigms.

Leaders must also develop robust strategies to integrate digital health solutions and data analytics into clinical decision-making processes. The use of predictive analytics can markedly enhance patient outcomes by pinpointing at-risk populations and customizing treatment plans accordingly. Diversifying product portfolios to cover not just advanced dialysis techniques but also a balanced mix of pharmacological and supportive care treatments is critical. Additionally, companies should invest in targeted educational initiatives to ensure that healthcare professionals remain well-versed in the latest clinical protocols and emerging treatment technologies.

A well-rounded approach also means paying close attention to regional market dynamics, tailoring products and services to meet localized demands while staying in lockstep with global best practices. Regulatory engagement is a key aspect of this strategy; staying abreast of policy changes and participating in industry forums fosters a proactive stance rather than a reactive one. Ultimately, by bolstering innovation, enhancing cross-sector collaboration, and leveraging digital transformation, industry leaders can secure a competitive advantage and better meet the evolving needs of patients worldwide.

Conclusion: Shaping the Future of AKI Treatment

In conclusion, the ongoing evolution of Acute Kidney Injury treatment is a testament to the dynamic nature of healthcare innovation. The comprehensive insights offered in this report underscore the critical role of advanced therapeutic modalities, robust segmentation analyses, and region-specific strategies in driving market growth. By exploring transformative shifts-from technological advancements in dialysis and pharmacological innovations to the integration of supportive care-stakeholders can appreciate the complexities and opportunities embedded within the market.

The analysis emphasizes the importance of a tailored approach, where segmented insights regarding treatment type, AKI classification, end user, and patient demographics converge to shape a more precise and personalized treatment methodology. Key regional insights reinforce the notion that geographical factors play a significant role in the adoption and success of these innovations. Meanwhile, a detailed overview of influential company players reflects the competitive spirit and collaborative efforts that are vital to sustaining market momentum.

These findings provide a roadmap not only for current decision-makers but also for future leaders eager to harness the potential of innovative technologies and integrated care strategies. In essence, the future of AKI treatment is being reimagined through relentless innovation, strategic partnerships, and a commitment to patient-centric care. This confluence of efforts ensures that as we move forward, the treatment and management of Acute Kidney Injury will continue to be refined, optimized, and more effectively implemented across the globe.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising geriatric population leading to a higher incidence of acute kidney injury globally
      • 5.1.1.2. Increasing prevalence of lifestyle diseases projected to boost acute kidney injury treatment demand
      • 5.1.1.3. Government initiatives and healthcare reforms promoting superior treatment infrastructure for kidney ailments
    • 5.1.2. Restraints
      • 5.1.2.1. Issues related to product recall associated with acute kidney injury treatment
    • 5.1.3. Opportunities
      • 5.1.3.1. Collaboration across healthcare sectors accelerates development of acute kidney injury therapies
      • 5.1.3.2. Improvements in diagnostic technologies aid in the early detection of acute kidney injury treatment
    • 5.1.4. Challenges
      • 5.1.4.1. Side effects and adverse reactions associated with current drug therapies limit their widespread use
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Treatment Type: Utilization of continuous renal replacement therapy due to its gentle and continuous filtration process
    • 5.2.2. Patient Demographics: Rising of acute kidney injury treatment in geriatric patients due to naturally diminishes kidney function
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Acute Kidney Injury Treatment Market, by Treatment Type

  • 6.1. Introduction
  • 6.2. Dialysis
    • 6.2.1. Continuous Renal Replacement Therapy (CRRT)
    • 6.2.2. Intermittent Hemodialysis
    • 6.2.3. Sustained Low-Efficiency Dialysis (SLED)
  • 6.3. Pharmacological Treatment
    • 6.3.1. Antibiotics
    • 6.3.2. Diuretics
    • 6.3.3. Pain Management Drugs
    • 6.3.4. Rehydration Drugs
  • 6.4. Supportive Care
    • 6.4.1. Dietary Management
    • 6.4.2. Fluid Management

7. Acute Kidney Injury Treatment Market, by AKI Type

  • 7.1. Introduction
  • 7.2. Intrinsic Renal Acute Kidney Injury
  • 7.3. Post-renal Acute Kidney Injury
  • 7.4. Pre-renal Acute Kidney Injury

8. Acute Kidney Injury Treatment Market, by End User

  • 8.1. Introduction
  • 8.2. Ambulatory Surgical Centers
  • 8.3. Hospitals
  • 8.4. Specialty Clinics

9. Acute Kidney Injury Treatment Market, by Patient Demographics

  • 9.1. Introduction
  • 9.2. Adult Patients
  • 9.3. Geriatric Patients
  • 9.4. Pediatric Patients

10. Americas Acute Kidney Injury Treatment Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Acute Kidney Injury Treatment Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Acute Kidney Injury Treatment Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2024
  • 13.2. FPNV Positioning Matrix, 2024
  • 13.3. Competitive Scenario Analysis
    • 13.3.1. Mitsui Chemicals invests in Rege Nephro for advancements in kidney disease treatment
    • 13.3.2. Unicycive completes successful phase 1 trial of UNI-494 for acute kidney injury treatment
    • 13.3.3. Baxter announces sale of Vantive kidney care segment to Carlyle for strategic focus and growth
  • 13.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Abbott Laboratories
  • 2. Alloksys Life Sciences B.V.
  • 3. Amgen Inc.
  • 4. Asahi Kasei Medical Co., Ltd.
  • 5. Astellas Pharma Inc.
  • 6. B. Braun Melsungen AG
  • 7. Baxter International, Inc.
  • 8. Bayer AG
  • 9. bioMerieux SA
  • 10. CardioRenal Systems, Inc.
  • 11. DaVita Inc. by Optum, Inc.
  • 12. Dr. Reddys Laboratories Ltd.
  • 13. Elicio Therapeutics Inc
  • 14. Fresenius Medical Care AG & Co. KGaA
  • 15. GlaxoSmithKline PLC
  • 16. Merck & Co., Inc.
  • 17. Nipro Corporation
  • 18. Novartis AG
  • 19. Otsuka Pharmaceutical Co., Ltd.
  • 20. Pfizer Inc.
  • 21. Silver Creek Pharmaceuticals, Inc.
  • 22. Sysmex Corporation
  • 23. Takeda Pharmaceutical Company Limited
  • 24. Teva Pharmaceutical Industries Ltd.

LIST OF FIGURES

  • FIGURE 1. ACUTE KIDNEY INJURY TREATMENT MARKET MULTI-CURRENCY
  • FIGURE 2. ACUTE KIDNEY INJURY TREATMENT MARKET MULTI-LANGUAGE
  • FIGURE 3. ACUTE KIDNEY INJURY TREATMENT MARKET RESEARCH PROCESS
  • FIGURE 4. ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, 2024 VS 2030
  • FIGURE 5. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 6. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 7. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2030 (%)
  • FIGURE 9. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY AKI TYPE, 2024 VS 2030 (%)
  • FIGURE 11. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY AKI TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY END USER, 2024 VS 2030 (%)
  • FIGURE 13. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 14. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2024 VS 2030 (%)
  • FIGURE 15. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 16. AMERICAS ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 17. AMERICAS ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 18. UNITED STATES ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY STATE, 2024 VS 2030 (%)
  • FIGURE 19. UNITED STATES ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 21. ASIA-PACIFIC ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 22. EUROPE, MIDDLE EAST & AFRICA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 23. EUROPE, MIDDLE EAST & AFRICA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 24. ACUTE KIDNEY INJURY TREATMENT MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 25. ACUTE KIDNEY INJURY TREATMENT MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. ACUTE KIDNEY INJURY TREATMENT MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. ACUTE KIDNEY INJURY TREATMENT MARKET DYNAMICS
  • TABLE 7. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY DIALYSIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY CONTINUOUS RENAL REPLACEMENT THERAPY (CRRT), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY INTERMITTENT HEMODIALYSIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY SUSTAINED LOW-EFFICIENCY DIALYSIS (SLED), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY DIALYSIS, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY ANTIBIOTICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY DIURETICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PAIN MANAGEMENT DRUGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY REHYDRATION DRUGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY SUPPORTIVE CARE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY DIETARY MANAGEMENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY FLUID MANAGEMENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY SUPPORTIVE CARE, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY AKI TYPE, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY INTRINSIC RENAL ACUTE KIDNEY INJURY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY POST-RENAL ACUTE KIDNEY INJURY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PRE-RENAL ACUTE KIDNEY INJURY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY ADULT PATIENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 33. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY GERIATRIC PATIENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 34. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PEDIATRIC PATIENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 35. AMERICAS ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 36. AMERICAS ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY DIALYSIS, 2018-2030 (USD MILLION)
  • TABLE 37. AMERICAS ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 38. AMERICAS ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY SUPPORTIVE CARE, 2018-2030 (USD MILLION)
  • TABLE 39. AMERICAS ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY AKI TYPE, 2018-2030 (USD MILLION)
  • TABLE 40. AMERICAS ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 41. AMERICAS ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 42. AMERICAS ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 43. ARGENTINA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 44. ARGENTINA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY DIALYSIS, 2018-2030 (USD MILLION)
  • TABLE 45. ARGENTINA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 46. ARGENTINA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY SUPPORTIVE CARE, 2018-2030 (USD MILLION)
  • TABLE 47. ARGENTINA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY AKI TYPE, 2018-2030 (USD MILLION)
  • TABLE 48. ARGENTINA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 49. ARGENTINA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 50. BRAZIL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 51. BRAZIL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY DIALYSIS, 2018-2030 (USD MILLION)
  • TABLE 52. BRAZIL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 53. BRAZIL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY SUPPORTIVE CARE, 2018-2030 (USD MILLION)
  • TABLE 54. BRAZIL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY AKI TYPE, 2018-2030 (USD MILLION)
  • TABLE 55. BRAZIL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 56. BRAZIL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 57. CANADA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 58. CANADA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY DIALYSIS, 2018-2030 (USD MILLION)
  • TABLE 59. CANADA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 60. CANADA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY SUPPORTIVE CARE, 2018-2030 (USD MILLION)
  • TABLE 61. CANADA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY AKI TYPE, 2018-2030 (USD MILLION)
  • TABLE 62. CANADA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 63. CANADA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 64. MEXICO ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 65. MEXICO ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY DIALYSIS, 2018-2030 (USD MILLION)
  • TABLE 66. MEXICO ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 67. MEXICO ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY SUPPORTIVE CARE, 2018-2030 (USD MILLION)
  • TABLE 68. MEXICO ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY AKI TYPE, 2018-2030 (USD MILLION)
  • TABLE 69. MEXICO ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 70. MEXICO ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 71. UNITED STATES ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 72. UNITED STATES ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY DIALYSIS, 2018-2030 (USD MILLION)
  • TABLE 73. UNITED STATES ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 74. UNITED STATES ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY SUPPORTIVE CARE, 2018-2030 (USD MILLION)
  • TABLE 75. UNITED STATES ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY AKI TYPE, 2018-2030 (USD MILLION)
  • TABLE 76. UNITED STATES ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 77. UNITED STATES ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 78. UNITED STATES ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 79. ASIA-PACIFIC ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 80. ASIA-PACIFIC ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY DIALYSIS, 2018-2030 (USD MILLION)
  • TABLE 81. ASIA-PACIFIC ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 82. ASIA-PACIFIC ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY SUPPORTIVE CARE, 2018-2030 (USD MILLION)
  • TABLE 83. ASIA-PACIFIC ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY AKI TYPE, 2018-2030 (USD MILLION)
  • TABLE 84. ASIA-PACIFIC ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 85. ASIA-PACIFIC ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 86. ASIA-PACIFIC ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 87. AUSTRALIA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 88. AUSTRALIA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY DIALYSIS, 2018-2030 (USD MILLION)
  • TABLE 89. AUSTRALIA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 90. AUSTRALIA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY SUPPORTIVE CARE, 2018-2030 (USD MILLION)
  • TABLE 91. AUSTRALIA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY AKI TYPE, 2018-2030 (USD MILLION)
  • TABLE 92. AUSTRALIA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 93. AUSTRALIA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 94. CHINA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 95. CHINA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY DIALYSIS, 2018-2030 (USD MILLION)
  • TABLE 96. CHINA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 97. CHINA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY SUPPORTIVE CARE, 2018-2030 (USD MILLION)
  • TABLE 98. CHINA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY AKI TYPE, 2018-2030 (USD MILLION)
  • TABLE 99. CHINA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 100. CHINA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 101. INDIA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 102. INDIA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY DIALYSIS, 2018-2030 (USD MILLION)
  • TABLE 103. INDIA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 104. INDIA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY SUPPORTIVE CARE, 2018-2030 (USD MILLION)
  • TABLE 105. INDIA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY AKI TYPE, 2018-2030 (USD MILLION)
  • TABLE 106. INDIA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 107. INDIA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 108. INDONESIA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 109. INDONESIA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY DIALYSIS, 2018-2030 (USD MILLION)
  • TABLE 110. INDONESIA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 111. INDONESIA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY SUPPORTIVE CARE, 2018-2030 (USD MILLION)
  • TABLE 112. INDONESIA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY AKI TYPE, 2018-2030 (USD MILLION)
  • TABLE 113. INDONESIA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 114. INDONESIA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 115. JAPAN ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 116. JAPAN ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY DIALYSIS, 2018-2030 (USD MILLION)
  • TABLE 117. JAPAN ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 118. JAPAN ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY SUPPORTIVE CARE, 2018-2030 (USD MILLION)
  • TABLE 119. JAPAN ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY AKI TYPE, 2018-2030 (USD MILLION)
  • TABLE 120. JAPAN ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 121. JAPAN ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 122. MALAYSIA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 123. MALAYSIA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY DIALYSIS, 2018-2030 (USD MILLION)
  • TABLE 124. MALAYSIA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 125. MALAYSIA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY SUPPORTIVE CARE, 2018-2030 (USD MILLION)
  • TABLE 126. MALAYSIA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY AKI TYPE, 2018-2030 (USD MILLION)
  • TABLE 127. MALAYSIA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 128. MALAYSIA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 129. PHILIPPINES ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 130. PHILIPPINES ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY DIALYSIS, 2018-2030 (USD MILLION)
  • TABLE 131. PHILIPPINES ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 132. PHILIPPINES ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY SUPPORTIVE CARE, 2018-2030 (USD MILLION)
  • TABLE 133. PHILIPPINES ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY AKI TYPE, 2018-2030 (USD MILLION)
  • TABLE 134. PHILIPPINES ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 135. PHILIPPINES ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 136. SINGAPORE ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 137. SINGAPORE ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY DIALYSIS, 2018-2030 (USD MILLION)
  • TABLE 138. SINGAPORE ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 139. SINGAPORE ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY SUPPORTIVE CARE, 2018-2030 (USD MILLION)
  • TABLE 140. SINGAPORE ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY AKI TYPE, 2018-2030 (USD MILLION)
  • TABLE 141. SINGAPORE ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 142. SINGAPORE ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 143. SOUTH KOREA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 144. SOUTH KOREA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY DIALYSIS, 2018-2030 (USD MILLION)
  • TABLE 145. SOUTH KOREA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 146. SOUTH KOREA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY SUPPORTIVE CARE, 2018-2030 (USD MILLION)
  • TABLE 147. SOUTH KOREA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY AKI TYPE, 2018-2030 (USD MILLION)
  • TABLE 148. SOUTH KOREA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 149. SOUTH KOREA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 150. TAIWAN ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 151. TAIWAN ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY DIALYSIS, 2018-2030 (USD MILLION)
  • TABLE 152. TAIWAN ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 153. TAIWAN ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY SUPPORTIVE CARE, 2018-2030 (USD MILLION)
  • TABLE 154. TAIWAN ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY AKI TYPE, 2018-2030 (USD MILLION)
  • TABLE 155. TAIWAN ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 156. TAIWAN ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 157. THAILAND ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 158. THAILAND ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY DIALYSIS, 2018-2030 (USD MILLION)
  • TABLE 159. THAILAND ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 160. THAILAND ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY SUPPORTIVE CARE, 2018-2030 (USD MILLION)
  • TABLE 161. THAILAND ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY AKI TYPE, 2018-2030 (USD MILLION)
  • TABLE 162. THAILAND ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 163. THAILAND ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 164. VIETNAM ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 165. VIETNAM ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY DIALYSIS, 2018-2030 (USD MILLION)
  • TABLE 166. VIETNAM ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 167. VIETNAM ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY SUPPORTIVE CARE, 2018-2030 (USD MILLION)
  • TABLE 168. VIETNAM ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY AKI TYPE, 2018-2030 (USD MILLION)
  • TABLE 169. VIETNAM ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 170. VIETNAM ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 171. EUROPE, MIDDLE EAST & AFRICA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 172. EUROPE, MIDDLE EAST & AFRICA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY DIALYSIS, 2018-2030 (USD MILLION)
  • TABLE 173. EUROPE, MIDDLE EAST & AFRICA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 174. EUROPE, MIDDLE EAST & AFRICA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY SUPPORTIVE CARE, 2018-2030 (USD MILLION)
  • TABLE 175. EUROPE, MIDDLE EAST & AFRICA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY AKI TYPE, 2018-2030 (USD MILLION)
  • TABLE 176. EUROPE, MIDDLE EAST & AFRICA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 177. EUROPE, MIDDLE EAST & AFRICA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 178. EUROPE, MIDDLE EAST & AFRICA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 179. DENMARK ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 180. DENMARK ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY DIALYSIS, 2018-2030 (USD MILLION)
  • TABLE 181. DENMARK ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 182. DENMARK ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY SUPPORTIVE CARE, 2018-2030 (USD MILLION)
  • TABLE 183. DENMARK ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY AKI TYPE, 2018-2030 (USD MILLION)
  • TABLE 184. DENMARK ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 185. DENMARK ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 186. EGYPT ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 187. EGYPT ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY DIALYSIS, 2018-2030 (USD MILLION)
  • TABLE 188. EGYPT ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 189. EGYPT ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY SUPPORTIVE CARE, 2018-2030 (USD MILLION)
  • TABLE 190. EGYPT ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY AKI TYPE, 2018-2030 (USD MILLION)
  • TABLE 191. EGYPT ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 192. EGYPT ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 193. FINLAND ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 194. FINLAND ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY DIALYSIS, 2018-2030 (USD MILLION)
  • TABLE 195. FINLAND ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 196. FINLAND ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY SUPPORTIVE CARE, 2018-2030 (USD MILLION)
  • TABLE 197. FINLAND ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY AKI TYPE, 2018-2030 (USD MILLION)
  • TABLE 198. FINLAND ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 199. FINLAND ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 200. FRANCE ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 201. FRANCE ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY DIALYSIS, 2018-2030 (USD MILLION)
  • TABLE 202. FRANCE ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 203. FRANCE ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY SUPPORTIVE CARE, 2018-2030 (USD MILLION)
  • TABLE 204. FRANCE ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY AKI TYPE, 2018-2030 (USD MILLION)
  • TABLE 205. FRANCE ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 206. FRANCE ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 207. GERMANY ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 208. GERMANY ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY DIALYSIS, 2018-2030 (USD MILLION)
  • TABLE 209. GERMANY ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 210. GERMANY ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY SUPPORTIVE CARE, 2018-2030 (USD MILLION)
  • TABLE 211. GERMANY ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY AKI TYPE, 2018-2030 (USD MILLION)
  • TABLE 212. GERMANY ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 213. GERMANY ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 214. ISRAEL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 215. ISRAEL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY DIALYSIS, 2018-2030 (USD MILLION)
  • TABLE 216. ISRAEL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 217. ISRAEL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY SUPPORTIVE CARE, 2018-2030 (USD MILLION)
  • TABLE 218. ISRAEL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY AKI TYPE, 2018-2030 (USD MILLION)
  • TABLE 219. ISRAEL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 220. ISRAEL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 221. ITALY ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 222. ITALY ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY DIALYSIS, 2018-2030 (USD MILLION)
  • TABLE 223. ITALY ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 224. ITALY ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY SUPPORTIVE CARE, 2018-2030 (USD MILLION)
  • TABLE 225. ITALY ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY AKI TYPE, 2018-2030 (USD MILLION)
  • TABLE 226. ITALY ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 227. ITALY ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 228. NETHERLANDS ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 229. NETHERLANDS ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY DIALYSIS, 2018-2030 (USD MILLION)
  • TABLE 230. NETHERLANDS ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 231. NETHERLANDS ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY SUPPORTIVE CARE, 2018-2030 (USD MILLION)
  • TABLE 232. NETHERLANDS ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY AKI TYPE, 2018-2030 (USD MILLION)
  • TABLE 233. NETHERLANDS ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 234. NETHERLANDS ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 235. NIGERIA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 236. NIGERIA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY DIALYSIS, 2018-2030 (USD MILLION)
  • TABLE 237. NIGERIA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 238. NIGERIA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY SUPPORTIVE CARE, 2018-2030 (USD MILLION)
  • TABLE 239. NIGERIA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY AKI TYPE, 2018-2030 (USD MILLION)
  • TABLE 240. NIGERIA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 241. NIGERIA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 242. NORWAY ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 243. NORWAY ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY DIALYSIS, 2018-2030 (USD MILLION)
  • TABLE 244. NORWAY ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 245. NORWAY ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY SUPPORTIVE CARE, 2018-2030 (USD MILLION)
  • TABLE 246. NORWAY ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY AKI TYPE, 2018-2030 (USD MILLION)
  • TABLE 247. NORWAY ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 248. NORWAY ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 249. POLAND ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 250. POLAND ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY DIALYSIS, 2018-2030 (USD MILLION)
  • TABLE 251. POLAND ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 252. POLAND ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY SUPPORTIVE CARE, 2018-2030 (USD MILLION)
  • TABLE 253. POLAND ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY AKI TYPE, 2018-2030 (USD MILLION)
  • TABLE 254. POLAND ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 255. POLAND ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 256. QATAR ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 257. QATAR ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY DIALYSIS, 2018-2030 (USD MILLION)
  • TABLE 258. QATAR ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 259. QATAR ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY SUPPORTIVE CARE, 2018-2030 (USD MILLION)
  • TABLE 260. QATAR ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY AKI TYPE, 2018-2030 (USD MILLION)
  • TABLE 261. QATAR ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 262. QATAR ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 263. RUSSIA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 264. RUSSIA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY DIALYSIS, 2018-2030 (USD MILLION)
  • TABLE 265. RUSSIA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 266. RUSSIA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY SUPPORTIVE CARE, 2018-2030 (USD MILLION)
  • TABLE 267. RUSSIA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY AKI TYPE, 2018-2030 (USD MILLION)
  • TABLE 268. RUSSIA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 269. RUSSIA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 270. SAUDI ARABIA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 271. SAUDI ARABIA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY DIALYSIS, 2018-2030 (USD MILLION)
  • TABLE 272. SAUDI ARABIA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 273. SAUDI ARABIA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY SUPPORTIVE CARE, 2018-2030 (USD MILLION)
  • TABLE 274. SAUDI ARABIA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY AKI TYPE, 2018-2030 (USD MILLION)
  • TABLE 275. SAUDI ARABIA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 276. SAUDI ARABIA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 277. SOUTH AFRICA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 278. SOUTH AFRICA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY DIALYSIS, 2018-2030 (USD MILLION)
  • TABLE 279. SOUTH AFRICA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 280. SOUTH AFRICA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY SUPPORTIVE CARE, 2018-2030 (USD MILLION)
  • TABLE 281. SOUTH AFRICA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY AKI TYPE, 2018-2030 (USD MILLION)
  • TABLE 282. SOUTH AFRICA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 283. SOUTH AFRICA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 284. SPAIN ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 285. SPAIN ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY DIALYSIS, 2018-2030 (USD MILLION)
  • TABLE 286. SPAIN ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 287. SPAIN ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY SUPPORTIVE CARE, 2018-2030 (USD MILLION)
  • TABLE 288. SPAIN ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY AKI TYPE, 2018-2030 (USD MILLION)
  • TABLE 289. SPAIN ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 290. SPAIN ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 291. SWEDEN ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 292. SWEDEN ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY DIALYSIS, 2018-2030 (USD MILLION)
  • TABLE 293. SWEDEN ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 294. SWEDEN ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY SUPPORTIVE CARE, 2018-2030 (USD MILLION)
  • TABLE 295. SWEDEN ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY AKI TYPE, 2018-2030 (USD MILLION)
  • TABLE 296. SWEDEN ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 297. SWEDEN ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 298. SWITZERLAND ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 299. SWITZERLAND ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY DIALYSIS, 2018-2030 (USD MILLION)
  • TABLE 300. SWITZERLAND ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 301. SWITZERLAND ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY SUPPORTIVE CARE, 2018-2030 (USD MILLION)
  • TABLE 302. SWITZERLAND ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY AKI TYPE, 2018-2030 (USD MILLION)
  • TABLE 303. SWITZERLAND ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 304. SWITZERLAND ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 305. TURKEY ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 306. TURKEY ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY DIALYSIS, 2018-2030 (USD MILLION)
  • TABLE 307. TURKEY ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 308. TURKEY ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY SUPPORTIVE CARE, 2018-2030 (USD MILLION)
  • TABLE 309. TURKEY ACUTE K